Your trusted source for investing success

Tag: breast cancer

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 
3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL™ Test for Hodgkin’s Lymphoma

3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL™ Test for Hodgkin’s Lymphoma

3D Signa­­­­­­tures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or “3DS”) is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HLTM, 3DS’ test in development for Hodgkin’s lymphoma (HL), shows that the Company’s TeloViewTM platform is able to distinguish, with a high degree of statistical significance,

JAMA Oncology Publication Demonstrates EndoPredict Significantly Outperforms Oncotype DX

Myriad Genetics (NASDAQ:MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.  A key finding is that Myriad’s EndoPredict® (EPClin) significantly outperformed Oncotype DX® Recurrence Score at predicting the risk of disease recurrence in patients with early-stage

Genetic Technologies Announces Strategic Alliance and Capital Raising

Genetic Technologies (NASDAQ:GENE) a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, is pleased to announce that it has entered into a non-binding terms sheet with Blockchain Global Limited ACN 601 628 497.

As quoted in the press release:
Dr Paul

BioCure Unaware of Any Material Change

BioCure Unaware of Any Material Change

Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the “Company” or “Biocure) At the request of IIROC, Biocure wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent

Rexahn Pharmaceuticals (NYSE:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/255,901, “Quinoxalinyl Piperazinamide Methods of Use”.

As quoted in the press release:
Peter D. Suzdak, Ph.D.,

Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations

Merus (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics announced that the first patient has been dosed in a Phase 2, open-label, multi-center international clinical trial to evaluate MCLA-128 in two metastatic breast cancer populations including HER2-positive MBC patients and hormone receptor positive/HER2-low MBC patients.

As quoted in the

What Is Genomics?

What Is Genomics?

Genomics, the study of genetic information within all living beings provides an insight into a patient’s genetics which opens the possibility to provide a more personalized medicine system.

MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis

MacroGenics (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced completion of a pre-planned interim futility analysis of the Phase 3 SOPHIA trial.

As quoted in the press release:
MacroGenics also announced today that the U.S. FDA has granted Fast

2018 Genetics Market Report


Find out what to watch for in the world of genetics investing.


Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
5 Pharmaceutical NASDAQ Micro-Cap Stocks

URL: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/pharma-micro-cap-stocks-nasdaq/